<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287623</url>
  </required_header>
  <id_info>
    <org_study_id>1301M27261</org_study_id>
    <nct_id>NCT02287623</nct_id>
  </id_info>
  <brief_title>Subcostal TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Donor Nephrectomy Patients: A Prospective Study</brief_title>
  <official_title>Subcostal TAP Block With Liposomal Bupivacaine vs Bupivacaine in Donor Nephrectomy Patients: A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is whether one local anesthetic, liposomal bupivacaine,
      provides improved pain control and decreased opioid use compared to bupivacaine when injected
      during a transversus abdominis plane block for donor nephrectomy patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is whether one local anesthetic, liposomal bupivacaine,
      provides improved pain control and decreased opioid use compared to bupivacaine when injected
      during a transversus abdominis plane block for donor nephrectomy patients.

      Background and treatment procedure: Liposomal bupivacaine is a multi vesicular formulation of
      bupivacaine that has been shown to provide up to 72 hours of analgesia compared to
      bupivacaine which provides up to 24 hours of analgesia post injection. These two medications
      have been compared using a infiltration or injection at the site of incision but have yet to
      be compared when used during a TAP block. A TAP block is an injection of local anesthetic
      under the covering of the transversus abdominis muscle layer. This layer is found using an
      ultrasound which is a beam of high frequency sound that allows one to visualize images in the
      body. Then using this ultrasound we can see our needle as it pierces the covering of the
      transversus abdominis muscle layer and watch as the local anesthetic is injected into this
      plane. This is done on both sides of the abdomen to provide analgesia to the skin, muscle,
      and fascial layers of the abdomen.

      Population: Adult patients who are undergoing a donor nephrectomy Rationale: It will be
      useful to determine if one formulation or the other provides better and longer lasting pain
      control for patients undergoing abdominal procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Scale</measure>
    <time_frame>48-72 hours after injection</time_frame>
    <description>This was a measure of patient's reported pain on a 0-10 verbal numerical rating scale. 10 being worst pain. The maximal value for the time period 48-72 hours was chosen as the maximal pain during that time period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Operative Opioid Use</measure>
    <time_frame>48-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Post Operative Nausea/Vomiting</measure>
    <time_frame>0-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Length of Stay</measure>
    <time_frame>up to 30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Opioid Use</measure>
    <time_frame>24-48 hours</time_frame>
    <description>Use of opioids during 24-48 hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Opioid Use</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Post operative opioid use from 0-24 hours after surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>liposomal bupivacaine TAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a TAP block with liposomal bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine TAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a TAP block with bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal bupivacaine</intervention_name>
    <description>patients will receive a tap with liposomal bupivacaine</description>
    <arm_group_label>liposomal bupivacaine TAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine</intervention_name>
    <description>patients will receive a tap with bupivacaine</description>
    <arm_group_label>bupivacaine TAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presenting for donor nephrectomy

        Exclusion Criteria:

          -  non english speaking

          -  chronic pain condition

          -  taking chronic opioids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <results_first_submitted>August 10, 2015</results_first_submitted>
  <results_first_submitted_qc>October 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2015</results_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Bupivacaine TAP</title>
          <description>Patients will receive a TAP block with liposomal bupivacaine
liposomal bupivacaine: patients will receive a tap with liposomal bupivacaine in the preoperative area before the kidney donation. This occurred under ultrasound guidance with the patient sedated. the patient received 30 mL total per tap. Each TAP consisted of 10 mL of liposomal bupivacaine and 20 mL of normal saline.</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine TAP</title>
          <description>Patients will receive a TAP block with bupivacaine bupivacaine: patients will receive a tap with bupivacaine in the preoperative area before the kidney donation. This occurred under ultrasound guidance with the patient sedated. the patient received 30 mL total per tap. Each TAP consisted of 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>we analyzed patients age, weight and gender.</population>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Bupivacaine TAP</title>
          <description>Patients will receive a TAP block with liposomal bupivacaine
liposomal bupivacaine: patients will receive a tap with liposomal bupivacaine</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine TAP</title>
          <description>Patients will receive a TAP block with bupivacaine
bupivacaine: patients will receive a tap with bupivacaine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.7" spread="12.3"/>
                    <measurement group_id="B2" value="75.5" spread="15.5"/>
                    <measurement group_id="B3" value="77.1" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numerical Rating Scale</title>
        <description>This was a measure of patient's reported pain on a 0-10 verbal numerical rating scale. 10 being worst pain. The maximal value for the time period 48-72 hours was chosen as the maximal pain during that time period.</description>
        <time_frame>48-72 hours after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with liposomal bupivacaine
liposomal bupivacaine: patients will receive a tap with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with bupivacaine
bupivacaine: patients will receive a tap with bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Rating Scale</title>
          <description>This was a measure of patient's reported pain on a 0-10 verbal numerical rating scale. 10 being worst pain. The maximal value for the time period 48-72 hours was chosen as the maximal pain during that time period.</description>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Opioid Use</title>
        <time_frame>48-72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with liposomal bupivacaine
liposomal bupivacaine: patients will receive a tap with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with bupivacaine
bupivacaine: patients will receive a tap with bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Opioid Use</title>
          <units>micrograms of fentanyl equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="30" upper_limit="170"/>
                    <measurement group_id="O2" value="170" lower_limit="65" upper_limit="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Post Operative Nausea/Vomiting</title>
        <time_frame>0-72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with liposomal bupivacaine
liposomal bupivacaine: patients will receive a tap with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with bupivacaine
bupivacaine: patients will receive a tap with bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Post Operative Nausea/Vomiting</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Length of Stay</title>
        <time_frame>up to 30 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with liposomal bupivacaine
liposomal bupivacaine: patients will receive a tap with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with bupivacaine
bupivacaine: patients will receive a tap with bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Length of Stay</title>
          <units>HOURS</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7" lower_limit="55.4" upper_limit="77.8"/>
                    <measurement group_id="O2" value="78.1" lower_limit="62.8" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Opioid Use</title>
        <description>Use of opioids during 24-48 hours after surgery</description>
        <time_frame>24-48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with liposomal bupivacaine
liposomal bupivacaine: patients will receive a tap with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with bupivacaine
bupivacaine: patients will receive a tap with bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Opioid Use</title>
          <description>Use of opioids during 24-48 hours after surgery</description>
          <units>Micrograms of fentanyl equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" lower_limit="100" upper_limit="335"/>
                    <measurement group_id="O2" value="240" lower_limit="125" upper_limit="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Opioid Use</title>
        <description>Post operative opioid use from 0-24 hours after surgery.</description>
        <time_frame>0-24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with liposomal bupivacaine
liposomal bupivacaine: patients will receive a tap with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine TAP</title>
            <description>Patients will receive a TAP block with bupivacaine
bupivacaine: patients will receive a tap with bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Opioid Use</title>
          <description>Post operative opioid use from 0-24 hours after surgery.</description>
          <units>micrograms of fentanyl equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" lower_limit="107.5" upper_limit="322.5"/>
                    <measurement group_id="O2" value="230" lower_limit="100" upper_limit="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Bupivacaine TAP</title>
          <description>Patients will receive a TAP block with liposomal bupivacaine
liposomal bupivacaine: patients will receive a tap with liposomal bupivacaine</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine TAP</title>
          <description>Patients will receive a TAP block with bupivacaine
bupivacaine: patients will receive a tap with bupivacaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jacob Hutchins</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-9990</phone>
      <email>hutc0079@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

